Carboplatin trials for Breast cancer

All Carboplatin trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Carboplatin for Breast cancer

• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 325 locations
• A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
  NCT07102381 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 35 locations
• A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
  NCT07743190 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
  NCT06103864 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 320 locations
• A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
  NCT07441460 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
  NCT06234137 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• A Study for the Adjuvant Treatment of Breast Cancer
  NCT05420467 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female · 1 location
• A Study for the Neoadjuvant Treatment of Breast Cancer
  NCT05420454 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female · 1 location
• A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
  NCT07287995 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
  NCT06891833 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 30 locations
• A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
  NCT06926868 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 295 locations
• A Study of LY4175408 in Participants With Advanced Cancer
  NCT07046923 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 54 locations
• A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
  NCT06279364 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
  NCT06841354 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 280 locations
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors
  NCT04389632 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 158 locations
• Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
  NCT04329065 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
  NCT05883852 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
  NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
  NCT06492759 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• MicroRNA Profiles in Triple Negative Breast Cancer
  NCT04771871 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 4 locations
• NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
  NCT06845319 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
  NCT07016399 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
  NCT06637306 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
  NCT07396324 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
  NCT07283692 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
  NCT06227117 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
  NCT07394387 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
  NCT07340398 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
  NCT05485766 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
  NCT06318897 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Organoid-based Functional Precision Therapy for Advanced Breast Cancer
  NCT06102824 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
  NCT06245889 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations
• Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
  NCT04954599 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
  NCT07017673 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
  NCT05638594 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
  NCT07173751 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 161 locations
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
  NCT05579366 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 66 locations
• SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
  NCT06927180 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
  NCT05929768 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 963 locations
• Study of AVZO-021 in Patients With Advanced Solid Tumors
  NCT05867251 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
  NCT05981001 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
  NCT06797635 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
  NCT05901428 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
  NCT03606967 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
  NCT05900206 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
  NCT06291064 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 4 locations
• Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
  NCT07220135 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
  NCT05978648 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Carboplatin for Breast cancer?

48 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.